Background and Purpose-To define desirable target low-density lipoprotein (LDL) cholesterol levels for the prevention of stroke recurrence, a post hoc analysis was performed in the J-STARS study (Japan Statin Treatment Against Recurrent Stroke). Methods-Subjects (n=1578) were divided into groups based on mean value of postrandomized LDL cholesterol levels until the last observation in 20 mg/dL increments. Adjusted hazard ratios (HRs) and 95% confidence intervals were analyzed for each group, with adjustments for baseline LDL cholesterol, baseline body mass index, hypertension, diabetes mellitus, and statin usage. 
S
troke is a heterogeneous disease with different causes and may present with or without underlying arterial pathologies. Thus, the benefits of statins may depend on the stroke subtype. The recent J-STARS study (Japan Statin Treatment Against Recurrent Stroke) showed that although the rates of total stroke and transient ischemic attack (TIA) in patients treated with pravastatin are similar to those of nonstatin controls, the incidence of atherothrombotic stroke is lower. 1 In the SPARCL trial (Stroke Prevention by Aggressive Reduction in Cholesterol Levels), atorvastatin treatment was associated with a 16% reduction in the risk of recurrent stroke.
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On the basis of meta-analyses, a reduction in the risk of major vascular events has been observed with per-unit reductions in LDL cholesterol level independent of the baseline LDL cholesterol level, and the risk reduction for primary stroke prevention depends on the degree of LDL cholesterol reduction with statins. [3] [4] [5] For primary stroke prevention, reductions in LDL cholesterol levels to 30 to 53 mg/dL may be beneficial, possibly with an additional treatment combined with statin. 6, 7 However, a randomized study has not been conducted to define a desirable target LDL cholesterol level in the treatment of dyslipidemia with statins for either primary or secondary stroke prevention. Even for major cardiovascular event prevention, a recent population study reported that patients with LDL cholesterol levels of 70 to 100 mg/dL who were taking statins exhibited a lower risk than patients with LDL cholesterol levels between 100 and 130 mg/dL; however, no additional benefit is obtained by achieving LDL cholesterol levels of ≤100 mg/dL. 8 Therefore, the ideal LDL cholesterol level for secondary stroke prevention is still controversial.
We hypothesized that the desirable target LDL cholesterol levels for preventing stroke recurrence may differ among the stroke subtypes. To define desirable LDL cholesterol levels for the prevention of stroke recurrence, a post hoc analysis was conducted using J-STARS data.
Methods
The data that support the findings of this study are available from the corresponding author on reasonable request. Details of the rationale, study design, characteristics of the participants, and principal results in J-STARS have been published elsewhere. 1, 9 This study was conducted as a post hoc analysis of J-STARS under the health insurance system of Japan and in accordance with the Declaration of Helsinki and the Ethical Guidelines on Clinical Studies of the Ministry of Health, Labour and Welfare of Japan. This study was also approved by the Institutional Review Board of each participating center, and written informed consent was obtained from all patients.
Patients
Briefly, patients aged 45 to 80 years with a history of noncardioembolic ischemic stroke within the preceding 1 month to 3 years were enrolled from 123 centers between March 2004 and February 2009. All patients had a total cholesterol level between 180 and 240 mg/dL (4.65 and 6.21 mmol/L) at enrollment, without the use of statins. The major exclusion criteria included cerebral infarction of determined rare cause, infarction associated with catheterization or surgery, and preferred use of statins for the treatment of comorbid coronary artery disease.
Procedures
The 1578 patients were randomly allocated to the pravastatin group (10 mg/d) or the control group (793 versus 785 subjects). In the randomization process, prevalence rates of stroke subtype (atherothrombotic stroke), high blood pressure (≥150/90 mm Hg), and comorbidity of diabetes mellitus were dynamically balanced between the 2 groups. In the pravastatin group, administration was initiated within 1 month after randomization, and the treatment was continued until the final observation. Diet and exercise therapies were reinforced when the total cholesterol levels consistently exceeded 240 mg/dL at routine clinical visits. An increase of the pravastatin dose or the addition of other nonstatin drugs was allowed based on the decision of the primary physician but only when existing measures were insufficient. The use of statins other than pravastatin was prohibited. In the control group, the administration of any statin was prohibited.
After randomization, patients received follow-up examinations at 2 and 6 months and annually until the completion of the study. When a patient experienced recurrent stroke or other vascular events, information on the event was sent to the data center and managed by dedicated data managers. The measurements of total cholesterol, LDL cholesterol, triglyceride, and high-density lipoprotein cholesterol levels were performed as previously described. 1, 9 Treatment compliance was monitored at every clinical visit.
The primary end point was the onset of stroke or TIA. Secondary end points included the onset of each stroke subtype, myocardial infarction, vascular accident, death, or hospitalization. In particular, stroke and other vascular events were adjudicated by the central event evaluation committees. For the adjudication of events, the final decision was made by the consensus of all committee members. Additionally, the accuracy of all event adjudication was verified by a local neurologist or cardiologist in each participating center by collating it with the patient's medical records.
Statistical Analysis
In accordance with the intention-to-treat principle, the analysis set was defined as the intention-to-treat population, including all randomized patients. The distribution of the baseline characteristics among the LDL cholesterol level groups at baseline was compared using analysis of variance (for continuous variables) or χ 2 tests (for discrete variables).
In this post hoc analysis, we evaluated the relationships of 3 LDL cholesterol levels, namely, the baseline LDL cholesterol level, the postrandomized LDL cholesterol level until the last observation excluding the baseline, and the reduced LDL cholesterol level from the baseline to the postrandomized level, with various events, including stroke and TIA, all vascular events, stroke alone, atherothrombotic infarction, lacunar infarction, and intracranial hemorrhage. All vascular events included recurrent stroke, TIA, myocardial infarction, and vascular accidents, such as aortic dissection/rupture, pulmonary embolism, cardiac failure, organ/limb infarction, carotid endarterectomy, stenting, extracranial-intracranial bypass, and coronary artery bypass graft/ intervention. 10 Subjects were divided into groups according to their baseline LDL cholesterol level or postrandomized LDL cholesterol level (20 mg/dL intervals) and divided into tertiles based on the reduced LDL cholesterol level. Patients were excluded from the evaluation of postrandomized LDL cholesterol levels when they experienced an incident of interest before the first follow-up evaluation of LDL cholesterol levels. The Cox proportional hazard model was used for each LDL cholesterol level and selected covariates to estimate the adjusted hazard ratio (HR), the 95% confidence interval, and the trend test of the LDL cholesterol levels for the events. The factors with P<0.20 compared with the distribution of baseline characteristics among the groups of baseline LDL cholesterol levels were selected as covariates. In addition, the baseline LDL cholesterol level was added as a covariate to analyze the postrandomized and reduced LDL cholesterol levels. Among the LDL cholesterol level subgroups, the subgroup with the highest LDL cholesterol level served as the reference. In addition, to analyze the reduced LDL cholesterol level, the subgroup with the lowest level (included 0 mg/dL) served as the reference. Sensitivity analyses were also performed by excluding the subjects in the pravastatin group who displayed less than one-fourth adherence to the statin treatment and subjects in the control group who had taken any statin.
All analyses were conducted using SAS version 9.3 (Cary, NC.). The level of significance was set at P<0.05 (2 tailed).
Results
The baseline LDL cholesterol level was 129.4±24.4 mg/dL in all patients (Figure 1 ). The postrandomized LDL cholesterol level until the last observation was 104.1±19.3 mg/dL in the pravastatin group and 126.1±20.6 mg/dL in the control group. Within the baseline LDL cholesterol level subgroups, considerable differences were observed in body mass index, hypertension, diabetes mellitus, and statin usage (P<0.20; Table) .
The adjusted HRs for stroke and TIA, all vascular events, stroke alone, atherothrombotic infarction, lacunar infarction, and intracranial hemorrhage were not significantly associated with the baseline LDL cholesterol level after adjusting for body mass index, hypertension, diabetes mellitus, and statin usage (Figures 2 and 3) .
The adjusted HRs for stroke and TIA and all vascular events decreased in the postrandomized LDL cholesterol level subgroups (80-100 mg/dL) after adjustment for the baseline LDL cholesterol level, body mass index, hypertension, diabetes mellitus, and statin usage (P=0.23 and 0.25 for the trend, respectively; Figures 2). After adjusting for postrandomized LDL cholesterol levels, no additional reductions in HRs were obtained with the usage of statins for patients with stroke and TIA, all vascular events, and stroke alone. Slight further reductions in HRs tended to be observed with a greater reduction in postrandomized LDL cholesterol level compared with baseline in patients with stroke and TIA, all vascular events, and stroke alone (P=0.36, 0.37, and 0.50 for the trend, respectively; Figure 2 ). After adjusting for the reduced LDL cholesterol level, statin usage did not further reduce the incidence.
Analyses of atherothrombotic infarction, lacunar infarction, and intracerebral hemorrhage were also performed to examine the differences in the effects of the statin on stroke subtypes. The adjusted HR for atherothrombotic infarction significantly reduced with the usage of statin after adjusting baseline LDL cholesterol levels (HR, 0.39; 95% confidence interval, 0.19-0.83). The adjusted HR for atherothrombotic infarction did not decrease in any postrandomized LDL cholesterol level subgroup (P=0.50 for the trend; Figure 3A) . A significant reduction in the adjusted HR for atherothrombotic infarction was not observed based on the reduced LDL cholesterol level (P=0.47 for the trend). After adjusting for the postrandomized or reduced LDL cholesterol level, no further reduction in Figure 3B ). No significant reduction in the adjusted HR for lacunar infarction was observed in accordance with the reduced LDL cholesterol level (P=0.48 for the trend). The adjusted HR for intracranial hemorrhage did not show significant differences among the postrandomized (P=0.37 for the trend) and reduced LDL cholesterol level subgroups (P=0.92 for the trend; Figure 3C ).
Discussion
As expected from previous reports on the influence of statins on reducing the risk of major cardiovascular events, 3 the event rates of stroke and TIA, all vascular events, and stroke alone displayed low HRs in the subgroup that presented a postrandomized LDL cholesterol level of 80 to 100 mg/dL in this secondary stroke prevention study. Although the analyses were adjusted for statin usage, reductions in the incidences of stroke and TIA, all vascular events, and stroke alone may be still influenced by statin treatment when the postrandomized LDL cholesterol level was controlled at <100 mg/dL. Because this study is based on an intention-to-treat analysis, a small but influential set of subjects who received statins were included in the control group (Table I in the online-only Data Supplement). Similar trends were also observed in the sensitivity analyses (Figures I and II in the online-only Data Supplement).
As the previously reported J-STARS main results, 1 atherothrombotic infarction event significantly reduced with statin treatment after adjusting baseline LDL cholesterol levels. There might be 2 major mechanisms responsible for the reduction of atherothrombotic infarction: LDL cholesterol reduction and pleiotropic effects of statin. It has been reported that a relative risk of stroke shows linear decreases with reductions in LDL cholesterol. 5 However, no significant trend regarding the risk of atherothrombotic infarction with reductions in the LDL cholesterol levels has been observed ( Figure 3A) . However, previous studies have suggested that statins exert pleiotropic effects, including atheromatous plaque stabilization and anti-inflammatory effects, [11] [12] [13] [14] [15] [16] which potentially play a role in the suppression of stroke, particularly atherothrombotic infarction. J-STARS substudies have shown that pravastatin treatment reduces the high-sensitivity C-reactive protein level and the progression of carotid intima-media thickness. 10, 17 Statin treatment reduced atherothrombotic infarction events after adjusting with baseline LDL cholesterol levels but not with postrandomized or reduced LDL cholesterol levels. We did not find that the reduction in LDL cholesterol and the pleiotropic effects obtained after statin treatment significantly influence atherothrombotic infarction events, which might be because of the low power of this subanalysis.
In the SPARCL trial, the atorvastatin treatment was independently associated with the incidence of hemorrhagic stroke after adjusting for covariates, including the postrandomization blood pressure. 18 However, the postrandomization LDL cholesterol level was not independently associated with the incidence of hemorrhagic stroke in the atorvastatin group, with a postrandomization LDL cholesterol level of 72.9±0.5 mg/dL. In the J-STARS study, a significant increase in the incidence of intracranial hemorrhage was not observed both in any postrandomized or in any reduced LDL cholesterol level subgroup. And, no significant increase in the incidence of intracranial hemorrhage with statin treatment after adjusting with postrandomized or reduced LDL cholesterol levels. Therefore, we postulate that the intracranial hemorrhage incidence may not increase in individuals with LDL cholesterol levels even <100 mg/dL. However, the J-STARS study experienced only a limited number of patients with intracranial hemorrhage.
The incidence of lacunar infarction is effectively reduced by antihypertensive treatments. 19 In the J-STARS study, although systolic blood pressure was controlled at a similar level between the treatment groups, the incidence of lacunar infarction was slightly higher in the pravastatin group. 1 According to a previous population study, the incidence of lacunar infarction was elevated in individuals with higher LDL cholesterol levels at baseline. 20 However, no association between the incidence of lacunar infarction and the baseline LDL cholesterol levels was detected in this study. In contrast, the incidence of lacunar infarction was reduced in the subgroup with a postrandomized LDL cholesterol level of 100 to 120 mg/dL. Although there were no statistical significances, statin treatment tended to increase the incidence of lacunar infarction adjusting with postrandomized or reduced LDL cholesterol levels. Recently, lacunar infarction has been considered to present a similar cause as intracerebral hemorrhage, so-called cerebral small-vessel disease. 21 Evaluating the influence of statins on lacunar infarction might also reveal the effects of statins on intracerebral hemorrhage.
Stroke is a heterogeneous disease with different causes. In the J-STARS, noncardioembolic stroke patients, but no hemorrhagic stroke patients, were enrolled, including atherothrombotic infarction (25.4%) and lacunar infarction (63.8%) as the stroke event for enrollment. 1 In addition, 33 atherothrombotic 
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infarction events, 84 lacunar infarction events, and 22 intracranial hemorrhage events were recorded during the followup observation period in Japanese stroke centers, with 91.1% antiplatelet usage. As discussed above, potent differences in the influences of LDL cholesterol levels on stroke subtypes may occur. Therefore, we need to consider the most likely stroke subtype for each patient when setting the target LDL cholesterol level to be achieved by statin treatment.
The current study has certain limitations. First, this study was a post hoc analysis of a PROBE design study (Prospective Randomized Open, Blinded-Endpoint). Therefore, it is difficult to draw a definitive conclusion. Second, the small study sample size may not provide sufficient statistical power to adequately assess the effects of pravastatin. Third, post hoc analysis may lead to the possibilities of type I and II errors. Fourth, the subgroup of postrandomized LDL cholesterol level <80 mg/dL had a limited number of patients. Therefore, the results of this subgroup exhibit low reliability.
In conclusion, the composite risk of stroke and TIA reduced in the postrandomized LDL cholesterol level of 80 to 100 mg/ dL after adjusting for statin usage. This post hoc analysis revealed potent differences in the influences of LDL cholesterol levels and statin treatments on stroke subtypes. For the prevention of stroke and TIA incidence with statins, clinicians should consider the most likely stroke subtype in each patient when determining the desirable LDL cholesterol level to be achieved by statin treatment.
